Cardiovascular Health

Gaps in Warfarin Therapy for Atrial Fibrilation Revealed by Quest Diagnostics Health Trends™

Approximately one in two patients with atrial fibrillation do not optimally reduce their risk of stroke or bleeding when treated with the most widely prescribed oral-anticoagulant therapy, according to a Quest Diagnostics Health Trends study published in Circulation, the journal of the American Heart Association.

Read the press release.

Read the study.

Quest Diagnostics Health Trends™ study finds cholesterol levels stopped improving after 2008

Decades of declines in LDL cholesterol blood levels, a key marker of death risk from heart disease, abruptly ended in 2008, and may have stalled since, according to a multi-year, national study by Quest Diagnostics. The study, published in the peer-reviewed journal PLOS ONE, is the largest of LDL cholesterol levels in an American population, based on test results of nearly 105 million individual adult Americans.

Read the press release.

Read the study.

Quest Diagnostics Health Trends™ study examines vitamin D's effect on cholesterol

A new peer-reviewed Quest Diagnostics Health Trends™ study finds that vitamin D supplementation may not improve total cholesterol and other blood lipids, key markers of risk for cardiovascular disease.

The study, by researchers at Quest Diagnostics and The Rockefeller University, is the first large-scale examination of the clinical impact of correcting vitamin D deficiency on lipid levels and associated cardiovascular-disease risk. Circulation, a peer-reviewed journal of the American Heart Association, published the study.

Read the press release.

Read the study.